שווי פעילות לרווח לפני ריבית, מסים ופחת affimed.com (AFMD)

This chart of Affimed (AFMD) share prices demonstrates an EV/EBITDA multiple of . The business relies on developing health-enhancing products while operating within a stable geopolitical environment. However, risks stem from costly research and competition for market share with industry behemoths. To optimize processes, Affimed (AFMD) delegates production and testing to external contractors, focusing instead on innovations in cancer therapy.

To select high-quality assets, an investor must compare the total business value with its operational efficiency. This indicator assesses the ratio of enterprise value to earnings before interest, taxes, depreciation, and amortization, determining the capital payback period. For Affimed (AFMD), with its high-tech laboratories and rigorous antibody production cycle, the EV/EBITDA ratio—accounting for operating profit and depreciation on GURU.Markets—clearly demonstrates the extent to which the company is overvalued or undervalued.